| UHC UMR Medical and Drug | Qalsody® (Tofersen) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-05-01 |
| UHC UMR Medical and Drug | Tremfya® (Guselkumab) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-05-01 |
| UHC UMR Medical and Drug | Veopoz® (Pozelimab-Bbfg) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-05-01 |
| UHC UMR Medical and Drug | Viltepso® (Viltolarsen) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-05-01 |
| UHC UMR Medical and Drug | Vyondys 53® (Golodirsen) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-05-01 |
| UHC Commercial Medical & Drug | Adakveo® (Crizanlizumab-Tmca) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-05-01 |
| UHC Commercial Medical & Drug | Amondys 45® (Casimersen) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-05-01 |
| UHC Commercial Medical & Drug | Crysvita® (Burosumab-Twza) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-05-01 |
| UHC Commercial Medical & Drug | Exondys 51® (Eteplirsen) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-05-01 |
| UHC Commercial Medical & Drug | Ketalar® (Ketamine) and Spravato® (Esketamine) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-05-01 |